Ardent Health Appoints COO Dave Caspers as New CEO; Reaffirms 2026 Adjusted EBITDA Guidance
ARDT is trading near its 52-week low of $8.07 (15% above the low).
Summary
Ardent Health named COO Dave Caspers as its new CEO, replacing Martin J. Bonick, and reaffirmed its 2026 Adjusted EBITDA guidance.
Key Events · Executive and Board Changes · ARDT
-
CEO Appointment
Dave Caspers, previously Chief Operating Officer, was appointed President and Chief Executive Officer and joined the Board of Directors, effective June 2, 2026.
-
CEO Departure
Martin J. Bonick separated from the company and stepped down from his roles as President, CEO, and Board member, effective June 2, 2026. The company intends to disclose the terms of his separation in a future filing.
-
New CEO Compensation
Mr. Caspers' employment agreement includes an annual base salary of $900,000, a target annual bonus opportunity of 105% of base salary, and special one-time equity grants totaling $3,000,000 in aggregate grant date fair value (time-based and performance-based Restricted Stock Units).
-
Guidance Reaffirmed
The company reaffirmed its full-year 2026 Adjusted EBITDA guidance of $485 million to $535 million, despite observing volume softness across its portfolio in the second quarter.
Analysis · ARDT · Industrial Applications And Services
Ardent Health has appointed its Chief Operating Officer, Dave Caspers, as the new President and CEO, succeeding Martin J. Bonick. This leadership transition, an internal promotion, aims to sharpen the company's focus on operational efficiency and growth. The company also reaffirmed its full-year 2026 Adjusted EBITDA guidance, providing a degree of stability amidst the executive change. The new CEO's compensation package includes a significant equity grant, aligning his incentives with long-term performance.
At the time of this filing, ARDT was trading at $9.27 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $8.07 to $15.48. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.